A Double-blind, Placebo-controlled, Randomized Trial to Determine the Safety and Efficacy of EMA401 in Reducing 24-hour Average Pain Intensity Score in Patients With Painful Diabetic Neuropathy (EMPADINE)
Phase of Trial: Phase II
Latest Information Update: 09 Jan 2019
At a glance
- Drugs Olodanrigan (Primary)
- Indications Diabetic neuropathies
- Focus Therapeutic Use
- Acronyms EMPADINE
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 21 Dec 2018 Planned End Date changed from 19 Apr 2019 to 27 Apr 2020.
- 21 Dec 2018 Planned primary completion date changed from 12 Apr 2019 to 17 Apr 2020.
- 19 Mar 2018 Status changed from not yet recruiting to recruiting.